可生物降解胶原基质用于青光眼引流装置植入的临床与生物学评价
回顾性纳入68只难治性青光眼眼,比较传统Ahmed阀植入与使用Ologen-6或Ologen-7的BCM增强Ahmed阀植入(BAAVI)的术后成功率;Ologen-7组完全成功率和条件成功率最高,且Ologen-7酶降解速率显著慢于Ologen-6。
要点
- Ologen-7组完全成功率(IOP≤21 mmHg)66.7%,高于传统组29.2%和Ologen-6组40.0%。
- Ologen-7组条件成功率75.0%,高于传统组45.8%和Ologen-6组55.0%。
- Ologen-7酶降解速率12.5×10-3,显著慢于Ologen-6的28.8×10-3。
核心结论
- Ologen-7 BAAVI组手术成功率最高,术后抗青光眼药物依赖最低。
- 临床结果与基于酶降解程度和结构形态的不同生物学及理化性质相关。
研究设计与样本
- 回顾性病历审查后连续纳入68只难治性青光眼眼,术后随访至少6个月。
- 行BCM增强Ahmed阀植入(使用Ologen-6和Ologen-7)并与传统方法比较。
- 通过胶原酶在眼生理条件下的酶降解速率评估每种BCM的生物学性质。
主要发现
- 传统组、Ologen-6 BAAVI组和Ologen-7 BAAVI组完全成功率(目标IOP 1)分别为29.2%、40.0%和66.7%。
- 传统组、Ologen-6 BAAVI组和Ologen-7 BAAVI组完全成功率(目标IOP 2)分别为12.5%、30.0%和45.8%。
- 传统组、Ologen-6 BAAVI组和Ologen-7 BAAVI组条件成功率分别为45.8%、55.0%和75.0%。
- Ologen-7的酶降解速率为12.5×10-3,显著慢于Ologen-6的28.8×10-3。
- 各组平均年龄和术前IOP相似。
关键数值与推荐
- 完全手术成功定义为IOP≤21 mm Hg(IOP 1)或≤17 mm Hg(IOP 2)且不使用抗青光眼药物。
- 条件成功定义为IOP≤21 mm Hg,伴或不伴抗青光眼药物。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To characterize the clinical and biological properties of biodegradable collagen matrices (BCMs) for possible glaucoma drainage device implantation. METHODS: A total of 68 refractory glaucoma eyes, followed up postoperatively for at least 6 months, were consecutively enrolled after retrospective chart review. The BCM-augmented Ahmed valve implantations (BAAVI) using our Ologen-6 and Ologen-7 valves were performed and compared with a conventional method. Complete surgical success was defined as an IOP of ≤21 mm Hg (IOP 1) or ≤17 mm Hg (IOP 2) without antiglaucoma medications. Qualified success was defined as an IOP ≤21 mm Hg with or without antiglaucoma medications. The biological properties of each BCM were assessed by enzymatic degradation rates via collagenase under ocular physiological conditions. RESULTS: The mean ages and preoperative IOPs were similar for the groups. In the conventional, BAAVI with Ologen-6, and BAAVI with Ologen-7 groups, complete success rates with target IOP 1 were 29.2%, 40.0%, and 66.7%; those with target IOP 2 were 12.5%, 30.0%, and 45.8%; qualified success rates were 45.8%, 55.0%, and 75.0%, respectively. The enzymatic degradation rate of Ologen-7 was significantly slower than that of Ologen-6 (12.5 × 10-3 vs. 28.8 × 10-3). CONCLUSIONS: The surgical success rate was highest in the Ologen-7 BAAVI group, with the lowest dependency on postoperative antiglaucoma medication use compared with the conventional and Ologen-6 BAAVI groups. The clinical results correlated with the different biological and physicochemical properties based on the degree of enzymatic degradation and on the structural morphology.
引用
- Song M, Lee S, Choe D, et al. Clinical and Biological Evaluations of Biodegradable Collagen Matrices for Glaucoma Drainage Device Implantation. Invest Ophthalmol Vis Sci. 2017. PMID: 29049735. doi:10.1167/iovs.17-22579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。